Title: Seroprevalence of chikungunya and o'nyong-nyong viruses in Senegal, West Africa

-
- 4 Authors: Prince Baffour Tonto^{1,2}, Mouhamad Sy³, Ibrahima Mbaye Ndiaye³, Mariama
- 5 Toure³, Amy Gaye³, Mariama Aidara³, Amadou Moctar Mbaye³, Abdoulaye Kane Dia^{3,4},
- 6 Mamadou Alpha Diallo³, Jules Francois Gomis³, Mamadou Samba Yade³, Younous
- 7 Diedhiou³, Baba Dieye³, Khadim Diongue³, Mame Cheikh Seck³, Aida S. Badiane³,
- 8 Bobby Brooke Herrera^{1,2*}, Daouda Ndiaye³
-

Affiliations:

- 11 1 Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA
- 2 Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases
- and Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical
- School, New Brunswick, NJ, USA
- 3 International Research Training Center on Genomics and Health Surveillance
- (CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal
- 4 Laboratoire d'ecologie vectorielle et parasitaire
-
- ***Corresponding Author**: BBH, bherrera@globalhealth.rutgers.edu
-
-
-

Abstract

Background

- Arthritogenic alphaviruses such as chikungunya (CHIKV) and o'nyong-nyong (ONNV)
- viruses have shown capacity to cause widespread epidemics, with recurrent and
- sporadic outbreaks occurring throughout sub-Saharan Africa.

Methods

We analyzed the seroprevalence for CHIKV and ONNV in 470 non-febrile subjects from

three regions in Senegal (Sindia, 2018; Thies, 2018; and Kedougou, 2022/2023) using

retrospective samples. We assessed the presence of anti-CHIKV IgG and neutralizing

titers against CHIKV and ONNV via enzyme-linked immunosorbent assay (ELISA) and

microneutralization tests, respectively, and determined risk factors of CHIKV and ONNV

exposure by binary logistic regression.

Results

- The overall seroprevalence of anti-CHIKV IgG was 24.89% (117/470). Regional
- seroprevalences were 14.89% (14/94) in Sindia, 28.72% (27/94) in Thies, and 26.95%
- (76/282) in Kedougou. Among CHIKV IgG-positive samples, 29.91% (35/117) and
- 39.32% (46/117) had neutralizing antibodies against CHIKV and ONNV, respectively. Of
- the remaining samples, 20.51% (24/117) were equivocal and 10.26% (12/117) were
- negative. Multivariate analysis showed that residence in Thies significantly increased
- the likelihood of CHIKV infection (OR, 3.878; 95% CI: 0.783-19.205), whereas prior
- malaria infection reduced it (aOR, 0.121; 95% CI: 0.049-0.300). Conversely, older age
- (OR, 7.896; 95% CI: 1.500-41.556) and residence in Kedougou (OR, 3.180; 95% CI:

0.824-12.276) were significant risk factors for ONNV infection, with prior malaria

infection also linked to higher ONNV susceptibility (aOR, 6.961; 95% CI: 2.456-19.732).

Conclusions

 Our study confirms significant exposure to CHIKV and ONNV across Senegal, underscoring the importance of ongoing surveillance and alphavirus testing among the

population.

Author summary

 Arthritogenic alphaviruses, such as chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses have the potential to cause widespread epidemics, with recurrent and sporadic outbreaks occurring throughout sub-Saharan Africa. This study presents a retrospective evaluation of CHIKV and ONNV seroprevalence among non-febrile subjects from three regions in Senegal: Sindia, Thies, and Kedougou. Our analysis revealed regional variation in alphavirus seroprevalence, with 29.91% of subjects exhibiting neutralizing antibodies against CHIKV and 39.32% against ONNV. We identified that residence in Thies was a risk factor for CHIKV, while residence in Kedougou, a history of malaria, and older age were risk factors for ONNV. These findings suggest significant exposure to CHIKV and ONNV across Senegal, underscoring the importance of ongoing surveillance and alphavirus testing among the population.

Introduction

 Arboviruses transmitted by mosquitoes pose a growing global health threat, significantly impacting morbidity and mortality. Among these, chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses are notable members of the alphavirus genus, recognized for their substantial effects on human health (1, 2). CHIKV, first isolated in Tanzania in 1952, has caused major outbreaks across Africa, Asia, and the Americas (3-5). Its transmission primarily involves *Aedes* mosquitoes, and its capacity for widespread dissemination was highlighted by the 2004 epidemic that originated in Kenya and rapidly extended to various regions, including the Indian Ocean islands and South and Southeast Asia (1, 5-7). By 2011, CHIKV reached the Western Hemisphere, spreading through the Caribbean and South America by 2014, resulting in hundreds of thousands of infections (8-10). ONNV, identified in Uganda in 1959, has caused significant epidemics primarily in East and West Africa, with major outbreaks recorded in the 1950s and early 1990s

 (11-13). Transmitted by *Anopheles* mosquitoes, ONNV remains largely confined to the African continent (6). The first major epidemic occurred from 1959 to 1962, affecting over 2 million people across East and West Africa (14, 15). A subsequent outbreak from 1996 to 1997 primarily impacted Uganda, Kenya, and Tanzania, with infection rates ranging from 45-68% (14, 16). Despite its geographical confinement, ONNV has been detected in travelers returning from endemic regions (17).

 Clinically, infections with CHIKV and ONNV are generally self-limiting but can present a spectrum of symptoms including fever, arthralgia, rash, headache, and malaise (18, 19). CHIKV is particularly associated with persistent arthralgia in patients

 (20). Although ONNV is endemic to Africa, comprehensive data on its morbidity and mortality are limited due to inadequate surveillance. The clinical features of alphavirus infections closely resemble those caused by other pathogens including *Plasmodium* (malaria) or *Salmonella* (typhoid fever) species, which are endemic in many West African countries (21-26). This symptom overlap complicates diagnosis and can lead to underreporting of CHIKV and ONNV, as their symptoms may be misattributed to other febrile illnesses.

 In West Africa, including Senegal, autochthonous cases of CHIKV have been reported since 1960, with periodic outbreaks continuing up to 2023 (27-31). Despite these occurrences, current data on the seroprevalence of CHIKV and ONNV in Senegal remains limited. This study aims to address this knowledge gap by investigating the seroprevalence of CHIKV and ONNV in Senegal. Given the antigenic similarities between these viruses, our approach focuses on using microneutralization assays to help differentiate between them to provide a more in-depth understanding of their prevalence. By enhancing our knowledge of the epidemiological landscape of CHIKV and ONNV in Senegal, we hope to inform public health strategies and contribute valuable insights into the broader context of arboviral transmission in West Africa.

Methods

Study Population and Ethics Statement

 The samples included in our study were originally collected as part of malaria and non-malarial surveillance among residents of Thies, Sindia, and Kedougou, Senegal. Samples from Thies and Sindia were part of the surveillance of non-malarial febrile illnesses, while samples from Kedougou were part of genomic surveillance of malaria. Informed consent was obtained from all subjects and/or their legal guardians for the initial sample collection as well as for its future use. All methods were performed in accordance with the guidelines and regulations set forth by the Declaration of Helsinki. The primary studies under which the samples and data were collected received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding data were banked and de-identified prior to the analyses.

CHIKV viral like particle (VLP) ELISA

 CHIKV VLPs (20 ng per well; Native Antigen) were coated onto Nunc Maxisorp 96-well plates (ThermoFisher) overnight, followed by blocking (1X PBST, 1% BSA; ThermoFisher) for 1 hour, then washing (1X PBST three times) and incubation with primary antibodies for 2 hours (serum at 1:400 dilution) at room temperature. The plates were washed three times with 1X PBST and bound sera were reacted with secondary antibodies (anti-human IgG conjugated with horseradish peroxidase [HRP]; ThermoFisher), according to the manufacturer's instructions. The plates were washed three more times and allowed to develop with 1-Step TMB ELISA Substrate (ThermoFisher), according to the manufacturer's instructions. The OD at 450 nm was read with a reference wavelength of 650 nm using an ELISA reader (Diasource). We interpreted the ELISA assay as follows: 1) sample absorbance / negative control 134 absorbance \leq 1.5, negative; 2) sample absorbance / negative control absorbance $>$ 1.5, positive.

Serum Microneutralization Assays

 Microneutralization assays were performed to detect neutralizing antibodies against CHIKV and ONNV in samples that were IgG positive for CHIKV VLP. Sera were diluted in a two-fold series from 1:40 to 1:10,240 in PBS in a 96-well plate. For each dilution, contact was performed with 100 plaque forming units (PFU) of CHIKV (BEI Resources: NR-56523) or ONNV (BEI Resources: NR-51661) for one hour at 37°C in a 142 5% CO₂ incubator. The complexes were then added to Vero cells (ATCC) CCL-81, 1.3 x $10⁵$ cells per well. After 3-4 days of incubation, the cytopathogenic effects were investigated by 0.2% crystal violet (SigmaAldrich) staining. After staining for 2-4 hours, 145 the plates were washed with copious amounts of tap water. For negative controls, at least 3 alphavirus-naïve serum samples were used to incubate with CHIKV or ONNV 147 prior to pipetting onto the Vero cells per plate. For positive controls, 100 PFU of CHIKV or ONNV without any contact with serum were placed on Vero cells in triplicate per plate. The neutralizing titer was defined as the inverse of the highest dilution resulting in an infectious reduction of 50%. A titer lower than 1:40 was considered as negative if cytopathogenic effects were not observed. Samples were considered as positive if the titer was ≥1:40, i.e., positive for ONNV if ONNV titers were at least two-fold higher than CHIKV titers, and CHIKV positive if CHIKV titers were at least four-fold higher than ONNV titers (32). The threshold was lower for ONNV than CHIKV because of the unique one-way cross-reactivity between CHIKV and ONNV, i.e., CHIKV antibodies are more likely to cross-react with ONNV antigens than ONNV antibodies with CHIKV antigens (33). All other results were interpreted as equivocal. 20 Senegalese serum

 samples that were previously determined to be alphavirus-naïve, were used to validate the assay. Each assay used at least 4 alphavirus-naïve serum samples as negative

controls.

Statistical Analysis

 Categorical variables are represented as case counts and proportions. To estimate the association between seroprevalence of alphavirus and demographics factors, including age group, gender, city, and malaria status, univariate and multivariate binary logistic regression analyses were performed. The adjusted odd ratios of the independent variables were computed by adjusting for age and gender as confounding variables. Statistical analyses were conducted using IBM SPSS statistics software version 28. The map of Senegal, heatmap, and graph representing rates and 170 percentages of CHIKV and ONNV neutralizing antibodies were generated using R

version 4.3.2 and Prism version 10.2.0.

Results

 A total of 470 samples collected from non-febrile subjects were included in the study. These samples were collected from three locations in Senegal: Sindia (n=94), Thies (n=94), and Kedougou (n=282) (Table 1). The samples from Sindia and Thies were malaria-negative by rapid diagnostic testing, whereas the samples from Kedougou were from subjects with malaria (Table 1). Participants' ages ranged from 6 months to 85 years, with an overall median age of 21 years. The study population was comprised of 44.89% females (n=211) (Table 1).

182 **Table 1. Baseline characteristics and chikungunya virus (CHIKV) and o'nyong-**

183 **nyong virus (ONNV) serology**

188

184

185

186

187

189

190

 Among the samples tested (n=470) for CHIKV VLP IgG antibodies, 117 tested positive, indicating an overall alphavirus seroprevalence of 24.89% (Table 1). Seroprevalence rates varied by location. Sindia had a rate of 14.89% (14/94), Thies had 28.72% (27/94), and Kedougou had 26.95% (76/282). In the serological analysis, a multivariate logistic regression revealed that subjects over 40 years old were more likely to have been exposed to an alphavirus, based on IgG reactivity to CHIKV VLP (OR, 2.100; 95% CI: 1.107-3.986) (S1 Table). Additionally, being a resident of Thies (OR, 2.384; 95% CI: 1.151-4.939) and Kedougou (OR, 5.591; 95% CI: 3.001-10.418) were associated with increased odds having been exposed to an alphavirus, with the highest risk observed in Kedougou (S1 Table). Furthermore, subjects with prior history of malaria were also more likely to have been exposed to an alphavirus (aOR, 3.465; 95% CI: 2.253-5.328) (S1 Table).

 The prevalence of neutralizing antibodies against CHIKV and ONNV varied by location in Senegal. The prevalence rates of CHIKV neutralizing antibodies were 42.86% (6/14) in Sindia, 66.67% (18/27) in Thies, and 14.47% (11/76) in Kedougou (Fig. 1A). For ONNV, the neutralizing antibody prevalence rates of were 28.57% (4/14) in Sindia, 14.81% (4/27) in Thies, and 50% (38/76) in Kedougou (Table 1, Fig. 1A). Overall, 29.91% (35/117) had neutralizing antibodies against CHIKV, 39.32% (46/117) had neutralizing antibodies against ONNV, 20.51% (24/117) were equivocal for both CHIKV and ONNV, and 10.26% (12/117) were negative (Table 1). Moreover, of the subjects with CHIKV neutralizing antibodies, 94.29% had cross-neutralizing antibodies against ONNV (Fig. 1B-C). However, of the subjects with ONNV neutralizing antibodies, only 53.33% had cross-neutralizing antibodies against CHIKV (Fig. 1B-C).

 Fig. 1. Antibody neutralization against chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses in Senegal. A) Map depicts locations in Senegal (Sindia, Thies, and Kedougou) where samples were collected from non-febrile subjects. For each location, donut charts represent number and corresponding percentages of subjects with neutralizing antibodies against CHIKV and ONNV or equivocal and negative results. B) CHIKV virus-like particle IgG-positive samples were tested for neutralizing antibodies 222 against CHIKV and ONNV. Colors depict the 50% neutralizing antibody titers (NT50), each row represents one individual, and each column is the titer to CHIKV or ONNV. C) The percentage of NT50-confirmed CHIKV or ONNV subjects with cross-neutralizing antibodies to the heterologous virus.

255 **Table 2. Risk factors for NT50-confirmed chikungunya virus (CHIKV) infections in**

256 **Senegal**

257 OR- Odd ratio; aOR- adjusted odd ratio for sex and age

280 **Table 3. Risk factors for NT50-confirmed o'nyong-nyong virus (ONNV) infections**

281 **in Senegal**

Discussion

 Furthermore, the presence of neutralizing antibodies in our sample cohort— 29.91% for CHIKV and 39.32% for ONNV—underscores ongoing virus circulation and potential for outbreaks (Fig. 1A). Notably, the high prevalence of ONNV neutralizing antibodies in Kedougou (50%) compared to other regions points to specific regional vulnerabilities, possibly driven by the overlapping mosquito vectors for malaria and ONNV (Fig. 1A). We also found that a high percentage (94.29%) of subjects with CHIKV neutralizing antibodies also had cross-neutralizing antibodies against ONNV (Fig. 1B- C). Conversely, a smaller proportion (53.33%) of those with ONNV neutralizing antibodies demonstrated cross-neutralization against CHIKV (Fig. 1B-C). These findings corroborate a directional bias in immune cross-reactivity, where CHIKV exposure might confer broader immunity, potentially impacting subsequent ONNV infection dynamics. This asymmetric cross-reactivity could also be due to structural similarities in the viral envelope proteins of CHIKV and ONNV, with CHIKV eliciting a broader neutralizing response (33). This phenomenon is crucial for diagnostic tests, which may need differentiation between past infections of these two viruses based on neutralizing antibody profiles. Moreover, understanding the mechanisms behind this differential cross-reactivity could guide vaccine strategies where a vaccine against one virus might offer partial protection against the other, hence optimizing the control measures for both viruses in regions where they co-circulate.

 The higher prevalence observed in older age groups for CHIKV supports the notion that cumulative exposure over time contributes to higher exposure rates. This demographic insight is crucial for developing targeted public health strategies, especially for vaccine deployment and vector control initiatives. The absence of a

 similar age-related pattern for ONNV suggests different dynamics, potentially influenced by sporadic outbreaks rather than continuous exposure.

 Limitations of our study include the retrospective nature of sample collection, which may not capture the most recent trends in virus circulation, and the absence of entomological data to directly correlate vector abundance with seroprevalence rates. Moreover, without concurrent clinical data, we cannot definitively link our serological findings to symptomatic disease cases, potentially underestimating the true burden of these infections. Also, IgG positivity does not necessarily reflect ongoing acute infections but generally is a sign of previous exposure to the virus (resolved infection). The insights into antibody cross-reactivity are essential for the interpretation of seroprevalence data in regions endemic to both viruses, as they could lead to overestimations of immunity against one virus due to past exposure to the other. This is particularly relevant in vaccine efficacy trials and in the evaluation of natural immunity in the population.

 Conclusions drawn from our research illustrate the persistent circulation of CHIKV and ONNV in Senegal, necessitating sustained surveillance and public health preparedness to mitigate the impact of these and other arboviruses. The findings also emphasize the importance of ecological and demographic factors in shaping the epidemiology of these diseases, highlighting the need for comprehensive arbovirus control strategies that integrate vector management with community health initiatives. Future studies should aim to incorporate entomological and clinical data to provide a more holistic understanding of the transmission dynamics and to facilitate the development of targeted interventions, including vaccines and therapeutic measures.

Acknowledgements

- We would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson
- Medical School, and the Child Health Institute of New Jersey.

Conflicts of Interest

- BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company that develops
- diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.

Author Contributions

- Conceptualization: BBH
- Data curation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
- MCS, ASB, BBH, DN
- Formal analysis: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD,
- KD, MCS, ASB, BBH, DN
- Funding acquisition: BBH, DN
- Investigation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
- MCS, ASB, BBH, DN
- Methodology: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
- MCS, ASB, BBH, DN
- Project administration: BBH, DN

- Resources: BBH, DN
- Software: PBT, MS, BBH
- Supervision: BBH, MS, DN
- Validation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
- MCS, ASB, BBH, DN
- Visualization: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
- MCS, ASB, BBH, DN
- Writing original draft: PBT, BBH
- Writing review & editing: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY,
- YD, BD, KD, MCS, ASB, BBH, DN

References

1. Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al.

GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2:

Epidemiological distribution of o'nyong-nyong virus. Antiviral Res. 2019;172:104611.

2. Zaid A, Burt FJ, Liu X, Poo YS, Zandi K, Suhrbier A, et al. Arthritogenic

alphaviruses: epidemiological and clinical perspective on emerging arboviruses. Lancet

Infect Dis. 2021;21(5):e123-e33.

3. Renault P, Balleydier E, D'Ortenzio E, Baville M, Filleul L. Epidemiology of

 Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Med Mal Infect. 2012;42(3):93-101.

4. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus:

mapping the 64-year history. Int J Infect Dis. 2017;58:69-76.

5. Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and

Its Spread to New Regions in 2013-2014. J Infect Dis. 2016;214(suppl 5):S436-S40.

6. Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, et al.

GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5:

- Entomological aspects. Antiviral Res. 2020;174:104670.
- 7. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al.

Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,

October 2004. Am J Trop Med Hyg. 2008;78(2):333-7.

8. Fischer M, Staples JE, Arboviral Diseases Branch NCfE, Zoonotic Infectious

Diseases CDC. Notes from the field: chikungunya virus spreads in the Americas -

Caribbean and South America, 2013-2014. MMWR Morb Mortal Wkly Rep.

2014;63(22):500-1.

9. Manzoor KN, Javed F, Ejaz M, Ali M, Mujaddadi N, Khan AA, et al. The global

emergence of Chikungunya infection: An integrated view. Rev Med Virol.

2022;32(3):e2287.

10. Teixeira MG, Andrade AM, Costa Mda C, Castro JN, Oliveira FL, Goes CS, et al.

East/Central/South African genotype chikungunya virus, Brazil, 2014. Emerg Infect Dis.

2015;21(5):906-7.

11. Corbet PS, Williams MC, Gillett JD. O'Nyong-Nyong fever: an epidemic virus

disease in East Africa. IV. Vector studies at epidemic sites. Trans R Soc Trop Med Hyg.

1961;55:463-80.

- 12. Williams MC, Woodall JP, Corbet PS, Gillett JD. O'nyong-Nyong Fever: An
- Epidemic Virus Disease in East Africa. 8. Virus Isolations from Anopheles Mosquitoes.
- Trans R Soc Trop Med Hyg. 1965;59:300-6.
- 13. Lanciotti RS, Ludwig ML, Rwaguma EB, Lutwama JJ, Kram TM, Karabatsos N,
- et al. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence:
- genetic characterization of the virus. Virology. 1998;252(1):258-68.
- 14. Rezza G, Chen R, Weaver SC. O'nyong-nyong fever: a neglected mosquito-
- borne viral disease. Pathog Glob Health. 2017;111(6):271-5.
- 15. Williams MC, Woodall JP, Gillett JD. O'nyong-Nyong Fever: An Epidemic Virus
- Diesease in East Africa. Vii. Virus Isolations from Man and Serological Studies up to
- July 1961. Trans R Soc Trop Med Hyg. 1965;59:186-97.
- 16. Kiwanuka N, Sanders EJ, Rwaguma EB, Kawamata J, Ssengooba FP, Najjemba
- R, et al. O'nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and
- validation of a clinical case definition for surveillance purposes. Clin Infect Dis.
- 1999;29(5):1243-50.
- 17. Tappe D, Kapaun A, Emmerich P, Campos Rde M, Cadar D, Gunther S, et al.
- O'nyong-nyong virus infection imported to Europe from Kenya by a traveler. Emerg
- Infect Dis. 2014;20(10):1766-7.
- 18. Johnson BK. O'nyong-nyong virus disease. Arboviruses: CRC Press; 2019. p.
- 217-24.
- 19. Kucharz EJ, Cebula-Byrska I. Chikungunya fever. Eur J Intern Med.
- 2012;23(4):325-9.

20. Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al.

Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal

study. PLoS neglected tropical diseases. 2013;7(3):e2137.

21. Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, et al. A

multicountry molecular analysis of Salmonella enterica serovar Typhi with reduced

susceptibility to ciprofloxacin in sub-Saharan Africa. Clinical Infectious Diseases.

2016;62(suppl_1):S42-S6.

22. Badiane AS, Ngom B, Ndiaye T, Cunningham D, Campbell J, Gaye A, et al.

Evidence of Plasmodium vivax circulation in western and eastern regions of Senegal:

implications for malaria control. Malaria Journal. 2024;23(1):149.

23. Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An

epidemiological study to assess Plasmodium falciparum parasite prevalence and

malaria control measures in Burkina Faso and Senegal. Malaria journal. 2017;16:1-12.

24. Diallo M, Diongue K, Diagne G, Seck M, Ndiaye M, Dièye B, et al. Plasmodium

ovale wallikeri and Plasmodium ovale curtisi Malaria in Senegal in 2016. Bulletin de la

Société de pathologie exotique. 2017;110:286-90.

25. Dromigny J-A, Perrier-Gros-Claude J-D. Antimicrobial resistance of Salmonella

enterica serotype Typhi in Dakar, Senegal. Clinical infectious diseases. 2003;37(3):465-

6.

26. Harrois D, Breurec S, Seck A, Delauné A, Le Hello S, de La Gandara MP, et al.

Prevalence and characterization of extended-spectrum β-lactamase-producing clinical

Salmonella enterica isolates in Dakar, Senegal, from 1999 to 2009. Clinical

Microbiology and Infection. 2014;20(2):O109-O16.

485 **S1 Table. Risk factors for alphavirus exposure (chikungunya virus virus-like**

486 **particle IgG+) in Senegal.** OR- Odd ratio; aOR- adjusted odd ratio for sex and age.